99-6265. Registration and Listing Grassroots Meetings for Medical Device Manufacturers  

  • [Federal Register Volume 64, Number 49 (Monday, March 15, 1999)]
    [Notices]
    [Pages 12813-12814]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 99-6265]
    
    
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Food and Drug Administration
    
    
    Registration and Listing Grassroots Meetings for Medical Device 
    Manufacturers
    
    AGENCY: Food and Drug Administration, HHS.
    
    ACTION: Notice of meetings.
    
    -----------------------------------------------------------------------
    
    SUMMARY: The Food and Drug Administration (FDA) is announcing the 
    following two open public meetings: Registration and Listing Grassroots 
    Meetings. The topic to be discussed at these meetings is FDA's 
    intention to propose changes to the current medical device registration 
    and listing system. These meetings are being conducted to provide a 
    forum in which FDA can obtain industry views on changes to the device 
    registration and listing system that FDA is currently considering. The 
    changes being considered are aimed at streamlining the collection of 
    registration and listing data, improving the accuracy and quality of 
    the data in the system, and decreasing the time it takes manufacturers 
    to register their establishments and list their devices, while 
    ultimately reducing FDA's cost of maintaining the registration and 
    listing system.
    
    DATES: See Table 1 in the ``SUPPLEMENTARY INFORMATION'' section of this 
    document.
    
    ADDRESSES: See Table 1 in the ``SUPPLEMENTARY INFORMATION'' section of 
    this document.
    
    FOR FURTHER INFORMATION CONTACT:
        For general meeting program information: Bonnie H. Malkin, Office 
    of Health and Industry Programs (HFZ-200), Center for Devices and 
    Radiological Health, Food and Drug Administration, 1350 Piccard Dr., 
    Rockville, MD 20850, 301-443-2845.
    
         For registration information: Mark S. Roh, Pacific Region, Food 
    and Drug Administration, 1301 Clay St., suite 1180N, Oakland, CA 94612-
    5217, (FAX) 510-637-3977.
        Those persons interested in attending these meetings, should fax 
    their registration to 510-637-3977, including name and position/title, 
    company name, mailing address, and telephone and fax numbers. There is 
    no charge to attend these meetings, but advance registration is 
    requested due to limited seating. If you need special accommodations 
    due to a disability, please contact Mark S. Roh at least 7 days in 
    advance.
    SUPPLEMENTARY INFORMATION: Over the past one and a half years, FDA has 
    reviewed the entire registration and listing process to determine if 
    the process can be made more efficient and accurate. This was one of 
    many reengineering efforts conducted by the Center for Devices and 
    Radiological Health (CDRH). This reengineering effort has resulted in a 
    number of suggestions aimed at improving the registration and listing 
    process for both FDA and industry. These meetings will help FDA obtain 
    the medical device industry perspective on the changes under 
    consideration and suggestions for additional changes.
         Some of the changes that FDA is currently considering include the 
    following:
         (1) Require industry submission of registration and listing 
    information through the World Wide Web (WEB). What are the advantages 
    and disadvantages to industry and how would industry be affected if WEB 
    submissions were mandated?
         (2) Require that owners and parent companies register and list and 
    take responsibility for the registration and listing of their 
    establishments. What is the highest level in a company that should be 
    responsible for registration and listing and how should this level be 
    defined/described?
         (3) Require that additional data elements be submitted to FDA, 
    e.g., premarket submission numbers for those devices that have gone 
    through the premarket notification (510(k)), premarket approval, or 
    product development protocol process.
         (4) Because of the ease of submission through the WEB, require 
    that firms register and list within 5 days (current requirement is 30 
    days) of entering into an operation that requires registration and 
    listing.
         A summary report of the meetings will be available on the CDRH 
    website approximately 15 working days after the meetings. The CDRH home 
    page may be accessed at ``http://www.fda.gov/cdrh'' .
    
                                               Table 1.--Meeting Schedules
    ----------------------------------------------------------------------------------------------------------------
               Meeting Address                            Dates                                 Times
    ----------------------------------------------------------------------------------------------------------------
    Northern California Meeting           ....................................  ....................................
      Airport Hyatt, San Jose, 1740       Tuesday, April 20, 1999               Registration: 7:30 a.m.
       North First St., San Jose, CA                                            Meeting: 8:30 a.m. to 12 m.
       95112, 408-993-1234.
    Southern California Meeting           ....................................  ....................................
      FDA Los Angeles District Office,    Wednesday, April 21, 1999             Registration: 7:30 a.m.
       19900 MacArthur Blvd., suite 300,                                        Meeting: 8:30 a.m. to 12 m.
       Irvine, CA 92612, 949-798-7714.
    ----------------------------------------------------------------------------------------------------------------
    
    
    
    [[Page 12814]]
    
        Dated: March 9, 1999.
    William K. Hubbard,
     Acting Deputy Commissioner for Policy.
    [FR Doc. 99-6265 Filed 3-12-99; 8:45 am]
    BILLING CODE 4160-01-F
    
    
    

Document Information

Published:
03/15/1999
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice of meetings.
Document Number:
99-6265
Dates:
See Table 1 in the ``SUPPLEMENTARY INFORMATION'' section of this document.
Pages:
12813-12814 (2 pages)
PDF File:
99-6265.pdf